ProfileGDS5678 / 1415686_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 95% 93% 93% 93% 94% 94% 94% 93% 93% 93% 94% 93% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.1467994
GSM967853U87-EV human glioblastoma xenograft - Control 28.4431595
GSM967854U87-EV human glioblastoma xenograft - Control 37.9185393
GSM967855U87-EV human glioblastoma xenograft - Control 48.1072193
GSM967856U87-EV human glioblastoma xenograft - Control 58.0725593
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.0202894
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.9532594
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.0458494
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.915593
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.8072193
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.8976993
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.0946294
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.8667293
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.9556593